Comparing Upfront Payments among Multinational, Mid-Sized European, and Japanese Drug Firms
Continuing our focus on the licensing styles of different types of in-licensors of biotechnology, this month looks at the upfront payments made to biotech partners by the top 10 multinational drug companies, mid-sized Europeans, and Japanese drug firms.
You may also be interested in...
Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.
While the COVID-19 pandemic continued to dominate EU-wide medtech decisions in May, further analysis of the one-year delay to the EU’s new regulations revealed some unexpected consequences. Meanwhile, a new flurry of documents and decisions have been produced by the European Commission.
The European Medicines Agency’s clinical data publication policy is on hold, but calls are growing for the regulator to start publishing trial data for COVID-19 treatments and vaccines as soon as they are authorized in the EU.